selected scholarly activity
-
chapters
-
conferences
- ASSOCIATION BETWEEN STROKE KEY PERFORMANCE INDICATORS AND PATIENT OUTCOMES IN LOW-RESOURCE SETTINGS IN RWANDA: RESULTS FROM THE ORGANIZED STROKE CARE ACROSS INCOME LEVELS (OSCAIL) STUDY. International Journal of Stroke. 363-363. 2023
- DEVELOPING AN EVIDENCE-BASED MOBILITY INTERVENTION FOR STROKE SURVIVORS: A UNIQUE APPLICATION OF THE REHABILITATION TREATMENT SPECIFICATION SYSTEM FOR COMMUNITY HEALTH WORKERS. International Journal of Stroke. 358-358. 2023
- IMPLEMENTING KEY ELEMENTS OF STROKE UNIT CARE IN LOW RESOURCE SETTINGS: THE ORGANIZED STROKE CARE ACROSS INCOME LEVELS (OSCAIL) PROOF OF CONCEPT STUDY. International Journal of Stroke. 89-89. 2023
- PREDICTORS OF DISABILITY AND MORTALITY AMONG PEOPLE HOSPITALISED FOR STROKE IN LOW-RESOURCE SETTINGS: RESULTS FROM THE ORGANISED STROKE CARE ACROSS INCOME LEVELS (OSCAIL) STUDY. International Journal of Stroke. 372-372. 2023
- PRESSURE ULCER PREVALENCE AND CARE PRACTICES IN HOSPITALISED STROKE PATIENTS: DATA FROM OSCAIL STUDY. International Journal of Stroke. 226-227. 2023
- REAL-WORLD CHALLENGES IN IMPLEMENTING ACUTE STROKE CARE IN LOW RESOURCE SETTINGS IN INDIA- OSCAIL STUDY. International Journal of Stroke. 136-136. 2023
- SIX SIMPLE VARIABLE COLLECTION IN LOWRESOURCE SETTINGS: DATA FROM THE OSCAIL STUDY. International Journal of Stroke. 376-376. 2023
- STRATEGIES FOR SPECIALTY TRAINING OF HEALTHCARE PROFESSIONALS IN LOW-RESOURCE SETTINGS: A SYSTEMATIC REVIEW ON EVIDENCE FROM STROKE CARE. International Journal of Stroke. 122-122. 2023
- UNDERSTANDING THE FUNCTIONAL NEEDS OF COMMUNITY-DWELLING STROKE SURVIVORS IN RWANDA: A PROSPECTIVE OBSERVATIONAL COHORT STUDY. International Journal of Stroke. 380-380. 2023
- RESEARCH CAPACITY BUILDING IN LOW RESOURCE SETTINGS: STRATEGIES FOR BRINGING TOGETHER STROKE RESEARCH TEAMS. International Journal of Stroke. 272-272. 2022
- "Usual Care" Physical Rehabilitation Received by Patients in the ICU: Secondary Analysis of the CYCLE Pilot RCT. American Journal of Respiratory and Critical Care Medicine. 2021
- ANATOMY OF STROKE CARE IN UGANDA'S TERTIARY HOSPITALS: ORGANIZED STROKE CARE ACROSS INCOME LEVELS (OSCAIL) STUDY. International Journal of Stroke. 743-743. 2020
- BARRIERS AND FACILITATORS TO IMPLEMENTING ORGANIZED STROKE CARE IN INDIA: RESULTS FROM INDIA OF THE ORGANIZED STROKE CARE ACROSS INCOME LEVELS (OSCAIL STUDY). International Journal of Stroke. 329-329. 2020
- CAN STROKE UNIT CARE BE IMPLEMENTED IN UNDER-RESOURCED SETTINGS IN RWANDA? RESULTS FROM THE ORGANIZED STROKE CARE ACROSS INCOME LEVELS (OSCAIL) STUDY. International Journal of Stroke. 19-19. 2020
- Efficacy and safety of low-dose rivaroxaban on top of aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. European Heart Journal. 1449-1449. 2020
- IMPLEMENTING KEY ASPECTS OF STROKE CARE IN LOW-RESOURCE SETTINGS: RESULTS OF THE OSCAIL STUDY. International Journal of Stroke. 742-742. 2020
- OSACIL STUDY: SEX, ACCESS TO STROKE SERVICES, AND MORTALITY IN LOW-RESOURCE SETTINGS. International Journal of Stroke. 747-747. 2020
- OSCAIL STUDY: IMPROVING ACUTE STROKE SERVICES IN SOUTH AFRICA. International Journal of Stroke. 744-744. 2020
- Understanding the Black Box of Intensive Care Unit Rehabilitation Interventions with Mechanically Ventilated Patients: A Review of 87 Prospective Studies. American Journal of Respiratory and Critical Care Medicine. 2020
- Legacy of Lipid Lowering in Preventing Fatal and Non Fatal Cardiovascular Events in Individuals Without Cardiovascular Disease During 3 Years of Post Trial Observation in the HOPE 3 (Heart Outcomes Prevention Evaluation) Study. Circulation Research. E108-E108. 2019
- Legacy of Lipid Lowering in Preventing Fatal and Non Fatal Cardiovascular Events in Individuals Without Cardiovascular Disease During 3 Years of Post -Trial Observation in the Hope 3 (Heart Outcomes Prevention Evaluation 3) Study. Circulation. 2019
- Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. European Heart Journal. 1274-1274. 2019
- Risk factors and clinical outcomes in chronic CAD and PAD: an analysis of the randomized, double-blind COMPASS trial. European Heart Journal. 2472-2472. 2019
- Angiotensin-converting enzyme and type 2 diabetes risk: a Mendelian randomisation study. Diabetologia. S108-S108. 2019
- 240-LB: Angiotensin-Converting Enzyme and Type 2 Diabetes Risk: A Mendelian Randomization Study. Diabetes. 2019
- A RANDOMIZED TRIAL OF PROTON PUMP INHIBITORS VERSUS PLACEBO TO PREVENT UPPER GASTROINTESTINAL BLEEDING IN PATIENTS RECEIVING RIVAROXABAN OR ASPIRIN. Gastroenterology. S174-S174. 2019
- ADVERSE EVENTS RELATED TO PROTON PUMP INHIBITOR THERAPY. RESULTS OF A RANDOMIZED TRIAL OF PANTOPRAZOLE VERSUS PLACEBO WITH 53,152 PATIENT YEARS OF FOLLOW-UP. Gastroenterology. S173-S174. 2019
- Effect of Oral Factor Xa Inhibitors on the Risk of Subdural Hematoma: COMPASS trial Results and Systematic Review. Stroke. 2019
- CAN KEY ELEMENTS OF A STROKE UNIT BE IMPLEMENTED IN RESOURCE SCARCE SETTINGS? WHERE DO WE START ( THE OSCAIL STUDY). International Journal of Stroke. 74-74. 2018
- CHARACTERIZATION OF STROKES ADMITTED TO KALAFONG HOSPITAL, PRETORIA, SOUTH AFRICA DURING THE BASELINE PHASE OF THE OSCAIL STUDY. International Journal of Stroke. 202-202. 2018
- DATA FROM THE OSCAIL STUDY ON TIME FROM STROKE ONSET TO PRESENTATION AT 3 PUBLIC AFRICAN HOSPITALS: TWO IN RWANDA AND ONE IN SOUTH AFRICA. International Journal of Stroke. 201-201. 2018
- DEVELOPING REHABILITATION SPECIFIC TRAINING FOR ORGANIZED STROKE CARE IN LOW AND MIDDLE INCOME COUNTRIES: WHAT IS NEEDED AND HOW TO IMPLEMENT. International Journal of Stroke. 41-41. 2018
- MOBILITY-RELATED CARE AFTER STROKE IN THE RWANDAN AND SOUTH AFRICAN CONTEXT: IDENTIFYING OPPORTUNITIES FOR IMPROVEMENT THROUGH THE ORGANIZED STROKE CARE ACROSS INCOME LEVELS (OSCAIL) STUDY. International Journal of Stroke. 114-114. 2018
- THE EFFECT OF LOSS TO FOLLOW-UP ON ESTIMATING POST-STROKE FUNCTION AND MORTALITY IN LOW AND MIDDLE-INCOME COUNTRIES: LESSONS FROM THE OSCAIL STUDY. International Journal of Stroke. 110-110. 2018
- THE EFFECTIVENESS OF SUPPORT AND TRAINING FOR SETTING UP ORGANIZED STROKE CARE PATHWAYS IN IMPROVING THE CLINICAL OUTCOME FOLLOWING A STROKE (OSCAIL). International Journal of Stroke. 164-164. 2018
- THE OSCAIL STUDY: MONITORING ACUTE STROKE CARE SERVICES IN RWANDA AND SOUTH AFRICA. International Journal of Stroke. 194-194. 2018
- THERAPISTS' UNDERSTANDING OF THE CANADIAN BEST PRACTICE RECOMMENDATIONS FOR UPPER EXTREMITY REHABILITATION AFTER STROKE; AND BARRIERS AND FACILITATORS FOR THEIR IMPLEMENTATION. International Journal of Stroke. 170-170. 2018
- First Stroke Reduced 44 Percent by Well Tolerated Medications. Stroke Outcomes From the Heart Outcomes Prevention Evaluation 3 Study. Stroke. 2018
- Costs Impact Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial. Circulation. E456-E457. 2017
- Impact of Rivaroxaban Alone or in Combination With Aspirin versus Aspirin in Preventing Graft Occlusion in Patients With CABG Surgery COMPASS CABG. Circulation. 2017
- Marked Global Variability in Cost Effectiveness of Lipid-Lowering and Combination Antihypertensive Therapies in Primary Prevention: Analyses of the HOPE-3 Trial. Circulation. 2017
- Predictors of cognitive decline after cardiac surgery: an evaluation of the CABG off or on pump revascularization study (CORONARY) cohort. European Heart Journal. 445-446. 2017
- The Effect of Blood Pressure and Cholesterol Lowering on Cognition. Circulation. E703-E704. 2016
- [PP.26.05] BLOOD PRESSURE LOWERING IN INTERMEDIATE RISK PEOPLE WITHOUT VASCULAR DISEASE. Journal of Hypertension. e274-e275. 2016
- Initiative to streamline clinical trials (ISCT): Guidance for academic investigators/sponsors.. Journal of Clinical Oncology. 219-219. 2016
- Frequency of Intracranial Arterial Imaging and its Yield in Consecutive Patients with Non-lacunar Cryptogenic Ischemic Stroke: ESUS Global Registry. Stroke. 2016
- Most patients in stroke rehab are not eligible for independent walking interventions: Lessons from the IMPACT walking study. International Journal of Stroke. 7-7. 2015
- Prevalence of potential minor risk sources of embolism in patients with embolic stroke of undetermined source (ESUS) - A global survey. International Journal of Stroke. 12-12. 2015
- Global survey of the frequency of AF-associated stroke and its detection. International Journal of Stroke. 267-267. 2015
- Frequency Aad Features of Patients With Embolic Strokes of Underdetermined Source (esus): Esus Global Registry. Stroke. 2015
- Frequency and Features of Patients with Embolic Stroke of Undetermined Source(ESUS). Stroke. E267-E268. 2014
- Global Survey of the Diagnostic Evaluation and Management of Cryptogenic Ischemic Stroke. Stroke. E280-E281. 2014
- What About the Other 12 Hours? Development and Pilot Testing of a Novel Program to Increase Walking-Related Practice During Stroke Rehabilitation. Stroke. E286-E286. 2014
- Effects of Insulin Glargine on Left Ventricular Mass and Function in Patients With Dysglycemia. Circulation. 2014
- Outcome reduction with an initial glargine intervention and legacy effects (ORIGINALE). Diabetologia. S516-S516. 2014
- Effects of n-3 fatty acids on long-term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction. European Heart Journal. 352-352. 2013
- Cancer Outcomes in Patients With Dysglycemia on Basal Insulin: Results of the ORIGIN Trial. Diabetes. A98-A98. 2013
- Cancer Outcomes in Patients With Dysglycemia on Basal Insulin: Results of the ORIGIN Trial. Diabetes. A72-A72. 2013
- Effect of Basal Insulin Glargine and Omega 3 FA on Cognitive Decline and Dementia in People With Dysglycemia. Diabetes. A308-A308. 2013
- Handgrip Strength Is Associated With Glomerular Filtration Rate in Patients With Diabetes Type 2. Diabetes. A393-A393. 2013
- Handgrip Strength Predicts Cardiovascular Mortality: A Subanalysis of the ORIGIN Trial. Diabetes. A367-A367. 2013
- Incident cancers in people with dysglycemia and other cardiovascular risk factors: Cohort study of the ORIGIN trial.. Journal of Clinical Oncology. 1504-1504. 2011
- Development of the Self-management and Task-oriented Approach to Rehabilitation Training (START) at home: a knowledge translation study. Stroke. E505-E505. 2010
- 55 HEMODYNAMIC EFFECTS AND SAFETY OF ONE-MONTH SIMVASTATIN TREATMENT IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION. A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER TRIAL. Journal of Hepatology. S25-S25. 2008
- Glucose levels predict incident cardiovascular events in a large international multiethnic cohort. Circulation. 835-835. 2007
- Obesity metrics and their associations with type 2 diabetes and glucose levels in a large international multi-ethnic cohort. Circulation. 318-319. 2007
- Design and baseline characteristics of the DREAM (diabetes REduction assessment with ramipril and rosiglitazone medication) trial. Diabetes. A483-A483. 2004
- Beneficial effects of ramipril on cardiovascular events in high-risk patients older than 75 years of age: Secondary outcomes from the HOPE trial. Journal of the American College of Cardiology. 154-154. 2003
- Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk diabetic patients. Journal of the American College of Cardiology. 291-291. 2002
- Ramipril prevents major cardiovascular events in high-risk women: results of the HOPE trial. Journal of the American College of Cardiology. 290-291. 2002
- Impact of abdominal obesity on the occurrence of diabetes in subjects with ischemic cardiovascular disease. Circulation. 833-833. 2001
- Effects of ramipril on left ventricular mass and function in normotensive, high-risk patients with normal ejection fraction. A substudy of HOPE. Journal of the American College of Cardiology. 165A-165A. 2001
- Effects of ramipril on the incidence of myocardial infarction in high risk patients: The HOPE Study. Circulation. 705-705. 2000
- Renal insufficiency as a predictor of cardiovascular outcomes and impact of ramipril: The HOPE study. Circulation. 655-655. 2000
- Abdominal adiposity as a prognostic factor for persons at high risk of cardiovascular events. Journal of the American College of Cardiology. 284A-284A. 2000
- Impact of Ramipril and vitamin A on cerebrovascular events in the HOPE (Heart outcomes prevention evaluation) trial. Journal of the American College of Cardiology. 324A-324A. 2000
- Left ventricular hypertrophy predicts death and development of heart failure in high risk patients without systolic dysfunction. Journal of the American College of Cardiology. 212A-212A. 2000
- Prevention of heart failure by Ramipril in high risk patients without heart failure or systolic dysfunction. Journal of the American College of Cardiology. 203A-203A. 2000
- Ramipril prevents cardiovascular events in high risk diabetic participants: Results of the HOPE study. Journal of the American College of Cardiology. 301A-301A. 2000
- Results of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 185-185. 1999
- Albuminuria is highly prevalent and predicts cardiovascular events in high risk diabetic and nondiabetic patients. Circulation. 1245-1245. 1997
- Is there a gender bias in the cardiovascular drug treatment of high-risk women?. Circulation. 143-143. 1997
- Left ventricular hypertrophy is a potent independent risk factor for adverse cardiovascular outcomes. Circulation. 2600-2600. 1997
- PROPRANOLOL IN THE PREVENTION OF REBLEEDING FROM PORTAL HYPERTENSIVE GASTROPATHY - A MULTICENTER RANDOMIZED CONTROLLED TRIAL. Hepatology. 870-870. 1990
- HEMODYNAMIC EVENTS IN A PROSPECTIVE RANDOMIZED TRIAL OF PROPRANOLOL VS PLACEBO IN THE PREVENTION OF THE 1ST VARICEAL HEMORRHAGE. Hepatology. 1242-1242. 1988
- PROPRANOLOL IN THE PREVENTION OF 1ST HEMORRHAGE FROM ESOPHAGEAL-VARICES (EVH) - A MULTICENTER CONTROLLED TRIAL. Hepatology. 1220-1220. 1988
-
journal articles
- Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low-Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled Trial. Authors' Reply.. Alimentary Pharmacology and Therapeutics. 60:1652-1653. 2024
- Authors' Reply: Proton Pump Inhibitors May Cause a Decline in eGFR by Inhibiting Organic Cation Transporter 2-Dependent Creatinine Secretion.. Journal of the American Society of Nephrology. 35:1614. 2024
- Correction: Characterizing usual-care physical rehabilitation in Canadian intensive care unit patients: a secondary analysis of the Canadian multicentre Critical Care Cycling to Improve Lower Extremity Strength pilot randomized controlled trial.. Canadian Journal of Anaesthesia. 71:1573. 2024
- Improving analysis of cognitive outcomes in cardiovascular trials using different statistical approaches.. Trials. 25:644. 2024
- Characterizing usual-care physical rehabilitation in Canadian intensive care unit patients: a secondary analysis of the Canadian multicentre Critical Care Cycling to Improve Lower Extremity Strength pilot randomized controlled trial.. Canadian Journal of Anaesthesia. 71:1406-1416. 2024
- The cardiometabolic consequences of workplace sexual harassment. European Journal of Preventive Cardiology (EJPC). 31:1643-1644. 2024
- Relationships between ankle blood pressure indices and major adverse cardiovascular events in people with and without type 2 diabetes.. Cardiovascular Diabetology. 23:325. 2024
- Health-related quality of life with rivaroxaban plus aspirin vs. aspirin alone in chronic stable cardiovascular disease: Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial.. European Heart Journal Open. 4:oeae083. 2024
-
Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low‐dose rivaroxaban, or the combination: Secondary analysis of the
COMPASS randomised controlled trial. Alimentary Pharmacology and Therapeutics. 60:737-748. 2024 - Frailty May Blunt the Therapeutic Efficacy and Complication Risk Through Multipronged Mechanisms-REPLY.. Canadian Journal of Cardiology. S0828-282X(24)00927-9. 2024
- Effect of Peripheral Interventions in Patients with Peripheral Artery Disease Receiving Rivaroxaban and Aspirin: Analyses from the XATOA Registry. European Journal of Vascular and Endovascular Surgery. S1078-5884(24)00621-X. 2024
- Results of the COMPASS Trial Analyzed Using Win Ratio Compared With Conventional Analytic Approaches. Canadian Journal of Cardiology. 40:2171-2179. 2024
- The Effects of Pantoprazole on Kidney Outcomes. Journal of the American Society of Nephrology. 35:901-909. 2024
- Impact of Frailty on the Benefits of Dual Pathway Inhibition for the Secondary Prevention of Cardiovascular Events in the COMPASS Randomised Trial. Canadian Journal of Cardiology. S0828-282X(24)00506-3. 2024
- Clinical significance of new-onset atrial fibrillation in patients with coronary artery or peripheral artery disease: results from the COMPASS trial. Europace. 26:euae102.024. 2024
- Arm and ankle blood pressure indices, and peripheral artery disease, and mortality: a cohort study. European Heart Journal. 45:1738-1749. 2024
- Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. The Lancet Diabetes and Endocrinology. 12:306-319. 2024
-
Effect of basal insulin and omega 3 fatty acids on cognitive impairment in dysglycaemia: An exploratory analysis of the
ORIGIN trial. Diabetes, Obesity and Metabolism. 26:1180-1187. 2024 - Global stroke statistics 2023: Availability of reperfusion services around the world. International Journal of Stroke. 19:253-270. 2024
- Identifying the highest risk vascular patients: Insights from the XATOA registry. American Heart Journal. 269:191-200. 2024
- Bleeding Risk Prediction in Patients Treated with Antithrombotic Drugs According to the Anatomic Site of Bleeding, Indication for Treatment, and Time Since Treatment Initiation. TH Open. 08:e121-e131. 2024
- Corrigendum: Bleeding Risk Prediction in Patients Treated with Antithrombotic Drugs According to the Anatomic Site of Bleeding, Indication for Treatment, and Time Since Treatment Initiation. TH Open. 08:e1-e1. 2024
- The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective. American Journal of Cardiovascular Drugs. 24:117-127. 2024
- Visit-to-visit variability in multiple biological measurements and cognitive performance and risk of cardiovascular disease: A cohort study. Cerebral Circulation - Cognition and Behavior. 6:100223-100223. 2024
- Cognitive performance following stroke, transient ischaemic attack, myocardial infarction, and hospitalisation: an individual participant data meta-analysis of six randomised controlled trials. The Lancet Healthy Longevity. 4:e665-e674. 2023
- Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials. Lancet Neurology. 22:1140-1149. 2023
- Antiplatelet therapy and incident cognitive impairment or dementia—a systematic review and meta-analysis of randomised clinical trials. Age and Ageing. 52:afad197. 2023
- Assessing Limb Outcomes in Drug Trials in Peripheral Artery Disease: The Need for a Universal and Pragmatic Definition. European Journal of Vascular and Endovascular Surgery. 66:442-443. 2023
- The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial. European Heart Journal - Quality of Care and Clinical Outcomes. 9:502-510. 2023
- Effectiveness of interventions by non-professional community-level workers or family caregivers to improve outcomes for physical impairments or disabilities in low resource settings: systematic review of task-sharing strategies. Human Resources for Health. 21:48. 2023
- Strategies for specialty training of healthcare professionals in low-resource settings: a systematic review on evidence from stroke care. BMC Medical Education. 23:442. 2023
- Dietary intake and cardiovascular outcomes in patients with chronic vascular disease: insights from the COMPASS trial cohort. European Journal of Preventive Cardiology (EJPC). 30:709-718. 2023
- Health status and cognitive function for risk stratification in chronic coronary and peripheral artery disease. European Journal of Preventive Cardiology (EJPC). 30:535-545. 2023
- Comparator Groups in ICU-Based Studies of Physical Rehabilitation: A Scoping Review of 125 Studies. Critical Care Explorations. 5:e0917-e0917. 2023
- The predictive value of interarm systolic blood pressure differences in patients with vascular disease: Sub-analysis of the COMPASS trial. Atherosclerosis. 372:41-47. 2023
- A hybrid automated event adjudication system for clinical trials. Clinical Trials. 20:166-175. 2023
- Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial. American Heart Journal. 258:60-68. 2023
- Does GERAS DANCE improve gait in older adults?. Aging and Health Research. 3:100120-100120. 2023
- Effects of a Polypill, Aspirin, and the Combination of Both on Cognitive and Functional Outcomes. JAMA Neurology. 80:251-251. 2023
- The impact of HIV co-infection on presentation and outcome in adults with tuberculous pericarditis: Findings from the IMPI trial. SAMJ - South African Medical Journal. 113:1109-1115. 2023
- Vitamin D supplementation and adverse skeletal and non-skeletal outcomes in individuals at increased cardiovascular risk: Results from the International Polycap Study (TIPS)-3 randomized controlled trial. Nutrition, Metabolism and Cardiovascular Diseases. 33:434-440. 2023
- Impact of Rabeprazole on APO-Dabigatran Exposure in Healthy Volunteers. CJC OPEN. 5:1-7. 2023
- World-wide variations in tests of cognition and activities of daily living in participants of six international randomized controlled trials. Cerebral Circulation - Cognition and Behavior. 5:100176-100176. 2023
- Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 8:786-795. 2022
- Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 8:825-836. 2022
- Are clinical trials randomising households to lifestyle interventions to delay cognitive decline feasible? A pilot study to determine the beliefs, preferences, and deterrents for households impacted by dementia based on semi-structured interviews. BMC Geriatrics. 22:322. 2022
- Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. The Lancet Respiratory Medicine. 10:1160-1168. 2022
- Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. The Lancet Respiratory Medicine. 10:1169-1177. 2022
- Retention in RCTs of physical rehabilitation for adults with frailty: a systematic review and meta-analysis. Trials. 23:235. 2022
- Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events. JAMA network open. 5:e2243201-e2243201. 2022
- INTERBLEED: Design of an International Study of Risk Factors for Gastrointestinal Bleeding and Cardiovascular Events After Gastrointestinal Bleeding. CJC OPEN. 4:996-1005. 2022
- Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. European Heart Journal. 43:3542-3552. 2022
- DIETARY INTAKE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH CHRONIC VASCULAR DISEASE IN THE COMPASS TRIAL. Canadian Journal of Cardiology. 38:S217-S218. 2022
- Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. The Lancet. 400:832-845. 2022
- Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 8:462-473. 2022
- Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. Circulation. 145:1875-1877. 2022
- Impact of Bioelectrical Impedance–Guided Fluid Management and Vitamin D Supplementation on Left Ventricular Mass in Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial. American Journal of Kidney Diseases. 79:820-831. 2022
- The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges. CJC OPEN. 4:568-576. 2022
- Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial. Journal of Stroke and Cerebrovascular Diseases. 31:106404-106404. 2022
- Systematic review: patient-reported outcome measures of fatigue in inflammatory bowel disease. Fatigue: Biomedicine, Health and Behavior. 10:60-82. 2022
- Functional Abilities of an International Post-Stroke Population: Standard Assessment of Global Everyday Activities (SAGEA) Scale. Journal of Stroke and Cerebrovascular Diseases. 31:106329-106329. 2022
- FUNCTIONAL OUTCOMES OF INDIVIDUALS WITH CARDIOVASCULAR DISEASE AFTER GASTROINTESTINAL CANCER. Journal of Cancer Rehabilitation. 5:48-55. 2022
- Provision and use of physical rehabilitation services for adults with disabilities in Rwanda: A descriptive study. African Journal of Disability. 11:1004. 2022
- Standardized Assessment of Global activities in the Elderly scale in adult cardiac surgery patients. British Journal of Anaesthesia. 127:539-546. 2021
- Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. The Lancet. 398:1133-1146. 2021
- Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. European Heart Journal. 42:2995-3007. 2021
- Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. Stroke. 52:2494-2501. 2021
- Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. Heart. 107:1130-1137. 2021
- Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. Journal of the American College of Cardiology. 78:14-23. 2021
- The Relationship Between Glucose Control and Cognitive Function in People With Diabetes After a Lacunar Stroke. Journal of Clinical Endocrinology and Metabolism (JCEM). 106:1521-1528. 2021
- Recognising HIV infection in systems of care for stroke – Authors' reply. The Lancet. 397:794-795. 2021
- Polypill with or without Aspirin in Persons without Cardiovascular Disease. New England Journal of Medicine. 384:216-228. 2021
- Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries. Cardiovascular Research (CVR). 117:576-584. 2021
- Feasibility of studying the association between intraoperative regional cerebral oxygen saturation and postoperative functional decline (ReFUNCTION): a pilot sub-study of NeuroVISION-Cardiac Surgery. Canadian Journal of Anaesthesia. 67:1497-1506. 2020
- Promoting Independent Mobility-related Physical ACTivity (IMPACT) in an inpatient stroke rehabilitation unit: a proof-of-concept evaluation of self-management intervention. Disability and Rehabilitation. 42:3172-3181. 2020
- Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. Stroke. 51:2901-2909. 2020
- Stroke systems of care in low-income and middle-income countries: challenges and opportunities. The Lancet. 396:1443-1451. 2020
- Oral factor Xa inhibitors and risk of subdural hematoma. Neurology. 95:e480-e487. 2020
- Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. Circulation. 141:1841-1854. 2020
- Association of Blood Pressure Lowering With Incident Dementia or Cognitive Impairment. Journal of the American Medical Association (JAMA). 323:1934-1934. 2020
- MON-636 The Relationship Between Glucose Control & Cognitive Function in People with Diabetes After a Lacunar Stroke. Journal of the Endocrine Society. 4:mon-636. 2020
- Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). Circulation. 141:1141-1151. 2020
- ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study. Diabetes Care. 43:835-842. 2020
- Are large simple trials for dementia prevention possible?. Age and Ageing. 49:154-160. 2020
- Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. European Journal of Preventive Cardiology (EJPC). 27:296-307. 2020
- Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes. JAMA Neurology. 77:43-43. 2020
- Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. European Heart Journal. 40:3771-3778a. 2019
- Can occupational therapists integrate new evidence into guideline-informed practice? They can, they do, and you can too. Occupational Therapy Now. 21:9-11. 2019
- Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. Circulation. 140:1451-1459. 2019
- Cross-cultural adaptation and psychometric evaluation of the Singapore version of the Chedoke Arm and Hand Activity. Disability and Rehabilitation. 41:2570-2577. 2019
- 4112Risk factors and clinical outcomes in chronic CAD and PAD: an analysis of the randomized, double-blind COMPASS trial. European Heart Journal. 40:ehz745.0116. 2019
- Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. Journal of the American College of Cardiology. 74:1519-1528. 2019
- Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 157:682-691.e2. 2019
- Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. Circulation. 140:529-537. 2019
- Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology. 157:403-412.e5. 2019
- Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. Journal of the American College of Cardiology. 73:3271-3280. 2019
- The cost implication of primary prevention in the HOPE 3 trial. European Heart Journal - Quality of Care and Clinical Outcomes. 5:266-271. 2019
- Effects of basal insulin glargine and omega‐3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial. Diabetes, Obesity and Metabolism. 21:1502-1505. 2019
- Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?. European Heart Journal. 40:1466-1471. 2019
- Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study. European Journal of Preventive Cardiology (EJPC). 26:681-697. 2019
- Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. Thrombosis and Haemostasis. 119:576-585. 2019
- Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. International Journal of Stroke. 14:270-281. 2019
- Effects of blood pressure and lipid lowering on cognition. Neurology. 92:e1435-e1446. 2019
- Stroke Outcomes in the COMPASS Trial. Circulation. 139:1134-1145. 2019
- Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial. Diabetes Care. 42:142-147. 2019
- Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion. Journal of the American College of Cardiology. 73:121-130. 2019
- Comparison of the sensitivity to change of the Functional Independence Measure with the Assessment of Motor and Process Skills within different rehabilitation populations. Disability and Rehabilitation. 40:3177-3184. 2018
- Reliability and validity of the shortened Singapore versions of the Chedoke Arm and Hand Activity Inventory. International Journal of Rehabilitation Research. 41:297-303. 2018
- The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct. American Heart Journal. 206:72-79. 2018
- Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease (vol 374, pg 2032, 2016). New England Journal of Medicine. 379:1486-1486. 2018
- Impact of cost on use of non-vitamin K antagonists in atrial fibrillation patients in Ontario, Canada. Journal of Thrombosis and Thrombolysis. 46:310-315. 2018
- Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry. European Urology Focus. 4:694-701. 2018
- Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial. Journal of the American Heart Association. 7:e008918. 2018
- Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology. 71:2306-2315. 2018
- Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. JAMA cardiology. 3:225-225. 2018
- External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. European Heart Journal. 39:750-757a. 2018
- Identifying and Treating Young Patients at Risk for Cardiovascular Events. Journal of the American College of Cardiology. 71:303-305. 2018
- Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial. Canadian Journal of Cardiology. 34:38-44. 2018
- Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 391:205-218. 2018
- Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 391:219-229. 2018
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine. 377:1319-1330. 2017
- PREDICTORS OF COGNITIVE DECLINE AFTER CARDIAC SURGERY: AN EVALUATION OF THE CABG OFF OR ON PUMP REVASCULARIZATION STUDY (CORONARY) COHORT. Canadian Journal of Cardiology. 33:S36-S36. 2017
- Impact of Killing in War: A Randomized, Controlled Pilot Trial. Journal of Clinical Psychology. 73:997-1012. 2017
- 2202Predictors of cognitive decline after cardiac surgery: an evaluation of the CABG off or on pump revascularization study (CORONARY) cohort. European Heart Journal. 38:ehx502.2202. 2017
- Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial. Canadian Journal of Cardiology. 33:1027-1035. 2017
- Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial. American Society of Nephrology. Clinical Journal. 12:965-973. 2017
- Antithrombotic Treatments for Stroke Prevention in Elderly Patients With Nonvalvular Atrial Fibrillation: Drugs and Doses. Canadian Journal of Cardiology. 32:1108-1116. 2016
- Global Survey of the Frequency of Atrial Fibrillation–Associated Stroke. Stroke. 47:2197-2202. 2016
- Numbers can save lives: Janice Pogue (1962–2016). Clinical Trials. 13:464-465. 2016
- Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry. International Journal of Stroke. 11:526-533. 2016
- Nadroparin for the prevention of venous thromboembolism in nonsurgical patients: a systematic review and meta-analysis. Journal of Thrombosis and Thrombolysis. 42:90-98. 2016
- Age disparity in diagnostic evaluation of stroke patients: Embolic Stroke of Undetermined Source Global Registry Project. European Stroke Journal. 1:130-138. 2016
- Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine. 374:2009-2020. 2016
- Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. New England Journal of Medicine. 374:2032-2043. 2016
- Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine. 374:2021-2031. 2016
- Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). Diabetes Care. 39:709-716. 2016
- Rapid reversal of haematoma expansion associated with vitamin K antagonists. Lancet Neurology. 15:535-537. 2016
- Updated Meta-Analysis of Aspirin in Primary Prevention of Cardiovascular Disease. American Journal of Medicine. 129:e35-e36. 2016
- Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. Canadian Journal of Cardiology. 32:311-318. 2016
- Enhanced TRAP-induced platelet aggregation with dabigatran — Clinical perspective. Thrombosis Research. 138:61-62. 2016
- Physical activity and genetic predisposition to obesity in a multiethnic longitudinal study. Scientific Reports. 6:18672. 2016
- Net benefit of ticagrelor in patients with chronic kidney disease. Nature Reviews Nephrology. 12:10-11. 2016
- Obesity Genes and Risk of Major Depressive Disorder in a Multiethnic Population. Journal of Clinical Psychiatry. 76:e1611-e1618. 2015
- Global Survey of the Diagnostic Evaluation and Management of Cryptogenic Ischemic Stroke. International Journal of Stroke. 10:1031-1036. 2015
- The Safety of Eplerenone in Hemodialysis Patients. American Society of Nephrology. Clinical Journal. 10:1602-1608. 2015
- Development and Evaluation of Self-Management and Task-Oriented Approach to Rehabilitation Training (START) in the Home: Case Report. Physical Therapy. 95:934-943. 2015
- Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin. BMJ Evidence-Based Medicine. 20:117-117. 2015
- Mechanical left atrial appendage closure was noninferior and superior to warfarin in atrial fibrillation. ACP journal club. 162:JC4-JC4. 2015
- Obesity Genes and Risk of Major Depression in a Multiethnic Population. Canadian Journal of Diabetes. 39:S27-S27. 2015
- Does Lowering Blood Pressure With Antihypertensive Therapy Preserve Independence in Activities of Daily Living? A Systematic Review. American Journal of Hypertension. 28:273-279. 2015
- Management of bleeding with oral anticoagulants in patients with atrial fibrillation. Hamostaseologie. 35:351-357. 2015
- Prednisolone andMycobacterium indicus praniiin Tuberculous Pericarditis. New England Journal of Medicine. 371:1121-1130. 2014
- The Mini‐Mental State Examination, Clinical Factors, and Motor Vehicle Crash Risk. Journal of The American Geriatrics Society. 62:1419-1426. 2014
- Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. European Heart Journal. 35:1743-1751. 2014
- Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. Diabetologia. 57:1325-1331. 2014
- Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. The Lancet Diabetes and Endocrinology. 2:562-572. 2014
- Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: A subanalysis of the ORIGIN trial. International Journal of Cardiology. 174:458-461. 2014
- The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care. 37:1360-1366. 2014
- Myocardial Injury after Noncardiac Surgery. Anesthesiology. 120:564-578. 2014
- Does Task-Oriented Practice Improve Upper Extremity Motor Recovery after Stroke? A Systematic Review. ISRN Dentistry. 2014:1-10. 2014
- Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. European Heart Journal. 35:353-364. 2014
- Randomized Clinical Trials — Removing Unnecessary Obstacles. New England Journal of Medicine. 369:1061-1065. 2013
- Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events. Diabetes Care. 36:2466-2474. 2013
- Genetic Information and the Prediction of Incident Type 2 Diabetes in a High-Risk Multiethnic Population. Diabetes Care. 36:2836-2842. 2013
- Setting the record straight on TIDE: a lost opportunity for patients with diabetes. Diabetologia. 56:1884-1887. 2013
- Effects of n-3 fatty acids on long-term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction. European Heart Journal. 34:1966-1966. 2013
- Rationale and design of the Investigation of the Management of Pericarditis (IMPI) trial: A 2 × 2 factorial randomized double-blind multicenter trial of adjunctive prednisolone and Mycobacterium w immunotherapy in tuberculous pericarditis. American Heart Journal. 165:109-115.e3. 2013
- n-3 Fatty Acids and Cardiovascular Outcomes in Dysglycemia. New England Journal of Medicine. 367:1761-1761. 2012
- Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. European Journal of Preventive Cardiology (EJPC). 19:755-764. 2012
- Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine. 367:319-328. 2012
- n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. New England Journal of Medicine. 367:309-318. 2012
- Cognitive impairment and risk of cardiovascular events and mortality. European Heart Journal. 33:1777-1786. 2012
- Insulin resistance in patients with cirrhosis and portal hypertension. American Journal of Physiology - Gastrointestinal and Liver Physiology. 302:G1458-G1465. 2012
- Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. CANADIAN MEDICAL ASSOCIATION JOURNAL. 184:E329-E336. 2012
- Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. Diabetologia. 55:36-45. 2012
- The Fluid Study Protocol: A Randomized Controlled Study on the Effects of Bioimpedance Analysis and Vitamin D on Left Ventricular Mass in Peritoneal Dialysis Patients. Advances in peritoneal dialysis. Conference on Peritoneal Dialysis. 31:529-536. 2011
- Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal. Diabetes Care. 34:1265-1269. 2011
- Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia. 54:487-495. 2011
- The Polypill in the Prevention of Cardiovascular Diseases. Circulation. 122:2078-2088. 2010
- Anthropometric measures and glucose levels in a large multi-ethnic cohort of individuals at risk of developing type 2 diabetes. Diabetologia. 53:1322-1330. 2010
- Lipid lowering for primary prevention (vol 373, pg 1152, 2009). The Lancet. 374:28-28. 2009
- Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose. Journal of the American College of Cardiology. 53:2028-2035. 2009
- Lipid lowering for primary prevention. The Lancet. 373:1152-1155. 2009
- Erratum. Clinical Trials. 5:283-283. 2008
- Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose. Diabetes Care. 31:1007-1014. 2008
- Sensible guidelines for the conduct of large randomized trials. Clinical Trials. 5:38-39. 2008
- Specific barriers to the conduct of randomized trials. Clinical Trials. 5:40-48. 2008
- Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). American Heart Journal. 155:26.e1-26.e13. 2008
- Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. European Heart Journal. 28:1382-1388. 2007
- Effect of ramipril on the incidence of diabetes - Reply. New England Journal of Medicine. 356:523-524. 2007
- The authors reply [6]. New England Journal of Medicine. 356:523-524. 2007
- Rosiglitazone delays the development of diabetes mellitus (DREAM trial). Cleveland Clinic Journal of Medicine. 74:64-64. 2007
- Independent design and conduct of clinical trials. Clinical Trials. 3:503-507. 2006
- The DREAM trial – Authors' reply. The Lancet. 368:2050-2051. 2006
- Effect of Ramipril on the Incidence of Diabetes. New England Journal of Medicine. 355:1551-1562. 2006
- Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. The Lancet. 368:1096-1105. 2006
- Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: The Heart Outcomes Prevention Evaluation (HOPE)-2 trial. Canadian Journal of Cardiology. 22:47-53. 2006
- Long-Term Effects of Ramipril on Cardiovascular Events and on Diabetes. Circulation. 112:1339-1346. 2005
- Effects of Long-term Vitamin E Supplementation on Cardiovascular Events and Cancer. Journal of the American Medical Association (JAMA). 293:1338-1338. 2005
- Effects of long-term supplementation on and cancer vitamin E cardiovascular events - A randomized controlled trial. Journal of the American Medical Association (JAMA). 293:1338-1347. 2005
- Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE Study. Clinical Nephrology. 63:181-187. 2005
- Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. American Heart Journal. 149:54-60. 2005
- The HOPE (Heart Outcomes Prevention Evaluation) Study and its Consequences. Scandinavian Journal of Clinical and Laboratory Investigation. 65:143-156. 2005
- Effect of Ramipril in Reducing Sudden Deaths and Nonfatal Cardiac Arrests in High-Risk Individuals Without Heart Failure or Left Ventricular Dysfunction. Circulation. 110:1413-1417. 2004
- Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia. 47:1519-1527. 2004
- Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction. Journal of the American College of Cardiology. 43:2200-2206. 2004
- Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: Results of the HOPE Study. Kidney International. 65:1375-1380. 2004
- Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. European Heart Journal. 25:17-24. 2004
- Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. European Journal of Cardiovascular Prevention and Rehabilitation. 10:420-428. 2003
- Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. European Journal of Preventive Cardiology (EJPC). 10:420-428. 2003
- Conundrum of the HOPE study: Authors' reply. The BMJ. 327:682-682. 2003
- New Trial Data on Prevention: Potassium and CV Risk in Hope. PACE - Pacing and Clinical Electrophysiology. 26:1565-1565. 2003
- Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 107:1284-1290. 2003
- Preventing stroke with ramipril---authors' reply. The BMJ. 326:52-52. 2003
- Effects of Vitamin E on Cardiovascular and Microvascular Outcomes in High-Risk Patients With Diabetes. Diabetes Care. 25:1919-1927. 2002
- Effect of long-term therapy with ramipril in high-risk women. Journal of the American College of Cardiology. 40:693-702. 2002
- Ramipril and cardiovascular risk reduction - Response. Circulation. 105:A194-A195. 2002
- Urate levels as a predictor of cardiac deaths: causal relation or mere association?. European Heart Journal. 23:760-761. 2002
- A pill for every ill - Response. Circulation. 105:E82-E82. 2002
- Use of ramipril in preventing stroke: double blind randomised trial. The BMJ. 324:699-699. 2002
- Effect of ramipril and vitamin E on atherosclerosis - Response. Circulation. 105:E5-E6. 2002
- Ramipril and the Development of Diabetes. Journal of the American Medical Association (JAMA). 286:1882-1882. 2001
- Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril. Circulation. 104:1615-1621. 2001
- Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. ACC Cardiosource Review Journal. 10:25-25. 2001
- Effects of Ramipril on Coronary Events in High-Risk Persons. Circulation. 104:522-526. 2001
- Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial. ACP journal club. 134:629-629. 2001
- Effects of Ramipril and Vitamin E on Atherosclerosis. Circulation. 103:919-925. 2001
- Implications of the Heart Outcomes Prevention Evaluation (HOPE) for the treatment of patients at high cardiovascular risk; systolic versus diastolic pressure predictive value. Heart. 83. 2000
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. New England Journal of Medicine. 342:145-153. 2000
- Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients. New England Journal of Medicine. 342:154-160. 2000
- Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. The Lancet. 355:253-259. 2000
- Summary of Randomized Trials of Angiotensin Converting Enzyme Inhibitors. Clinical and Experimental Hypertension. 21:835-845. 1999
- The Study of Health Assessment and Risk in Ethnic groups (SHARE): rationale and design. The SHARE Investigators.. Canadian Journal of Cardiology. 14:1349-1357. 1998
- The study of health assessment and risk in ethnic groups (SHARE): Rationale and design. Canadian Journal of Cardiology. 14:1349-1357. 1998
- Rationale and Design of a Large Study to Evaluate the Renal and Cardiovascular Effects of an ACE Inhibitor and Vitamin E in High-Risk Patients With Diabetes: The MICRO-HOPE Study. Diabetes Care. 19:1225-1228. 1996
- Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation.. Diabetes Care. 19:1225-1228. 1996
- Collaborative cardiovascular clinical trials in Canada. The Canadian Cardiovascular Collaboration.. Canadian Journal of Cardiology. 11:649-657. 1995
- COST-EFFECTIVENESS STUDIES - CAN BENEFIT BE SHOWN ONLY IN HIGH-RISK POPULATIONS. British Journal of Clinical Practice. 22-25. 1995
-
preprints
-
theses